COLL Collegium Pharmaceutical, Inc.

10.75-0.09 (-0.83%)
IEX real time price: 12:36:58 PM

Quote

Previous Close
$10.84
Day Range
$10.61-$10.91
52 Week Range
$10.41-$21.20
Volume
74,642
Avg Volume
317,293
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$358.91M
Enterprise Value (EV)
$226.78M
PE Ratio
-
EV/EBITDA
2.51
Price/Sales
1.29
Price/Book
3.95
PEG Ratio
0.13

Financials

Revenue
$280.41M
Gross Profit
$114.74M
EBITDA
$90.22M
EPS, ttm
-$0.92
Profit Margin
-
Revenue/Employee
$1.05M
Next Earnings Date
8/8/2019 (21 days)
Debt to Equity
13%
Debt
$14.50M
Cash
$146.63M
Net Debt
-

Performance

Beta
0.84
200 Day Moving Avg
$15.29
50 Day Moving Avg
$12.26
52 Week Change
-44.52%
YTD Change
-39.93%
1 Month Change
-4.49%
3 Month Change
-19.82%
6 Month Change
-31.22%
1 Year Change
-44.52%
2 Year Change
93.54%
5 Year Change
19.53%

Share Count

Shares Outstanding
33.4M
Float
-
Restricted Shares
33.4M
Restricted Shares, %
100.00%

Collegium Pharmaceutical, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Other

CEO: Joseph J. Ciaffoni

Website: http://www.collegiumpharma.com

Description: Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Employees: 266